Clinical Research
As part of our mission to advance knowledge and treatment of vascular diseases and thrombotic disorders, Jefferson’s Center
for Vascular Diseases actively participates in numerous clinical studies. These studies provide our patients with access to
emerging treatments. Current studies include:
-
The Re-LY Study, a comparison of two doses of investigational drug Dabigatran (given by mouth) with Warfarin (given by mouth)
for a minimum of 12 months to a maximum time of three years for preventing strokes in patients with artrial fibrillation.
-
The Re-COVER Study, a comparison of two doses of investigational drug Dabigatran (given by mouth) with Warfarin (given by
mouth) for treatment of blood clots for a period of six months after standard treatment for five to 10 days with an injectable
blood thinner already approved by the Food and Drug Administration.
-
The Re-MEDY Study, a comparison of investigational drug Dabigatran (given by mouth) with Warfarin (given by mouth) for prevention
of blood clots.
-
Cassiopea, a comparison of new anticoagulant medication Biotinylated Idraparinux with the standard of care (Warfarin) in the
treatment of pulmonary embolism.
-
A study to evaluate the safety and effectiveness of investigational drug Rimonabant in people with obesity concentrated in
the abdominal area who have risk factors for the development of heart disease and/or diabetes and who currently have normal
cholesterol levels.
-
The IMPROVE Study, an informational gathering study to determine risk factors for the development of blood clots and the best
ways to prevent them in people who have medical problems and who have stayed in the hospital.
-
The Equinox Study, a comparison of two new forms of blood-thinning medicines (Idraparinux and Biotinylated Idraparinux) in
patients with clots in the legs and the ability of new medication Avidin in reversing the effects of Biotinylated Idraparinux.
To learn more about these studies, please contact Laurie DeSimone at 215-955-6540
